Biocon scheduled a board meeting on 6 December to review its investment in Biocon Biologics and assess a new fundraising plan. The exchange filing records the agenda items, financial matters listed for review and the official date shared by the company.
Source: Biocon Limited Press Release (BSE Exchange Filings) | Published on Dec 03, 2025
Disclaimer: This content has been published for informational purposes only. Bajaj Broking is not affiliated with, nor does it endorse or assume any responsibility for, the source material. Readers are advised to consult the original publication for complete and accurate context.
As quoted in the press release from Biocon and its news (BSE Exchange Filings), the company informed the exchange that its board will meet on 6 December to review matters related to Biocon Biologics and a separate fundraising plan. The filing outlines the scheduled agenda and the items that will be presented for review. The disclosure shares factual information in line with reporting requirements and lists the corporate matters placed before the board.
Also Read: Biocon Board to Review Biologics Investment and Fundraising Plan
Board meeting date: 6 December
Investment in Biocon Biologics is placed for review
Fundraising plan listed as an agenda item
Filing issued through the exchange
Biocon stated in its exchange notification that its board will meet on 6 December. The filing lists two agenda points: a review of the company’s investment in Biocon Biologics and an additional fundraising plan. The disclosure follows the mandated structure for corporate communication, presenting only confirmed items shared through the exchange.
The filing outlines the agenda without interpretive language. It provides a factual summary of the matters that will be placed before the board on the scheduled date. Biocon and share price discussions often refer to such filings when corporate actions appear in meeting agendas.
The company recorded its plan to review the investment in Biocon Biologics as a board agenda point. The exchange document lists this matter as part of the board’s scheduled examination of financial and business-related items. The update records the agenda without stating any potential decisions or outcomes.
The filing’s format aligns with corporate communication standards followed for Biocon and share price updates when investment-related matters are disclosed.
Biocon listed a fundraising plan as a separate agenda item in the exchange communication. The filing states that the matter will be considered by the board during the meeting. The document offers no additional details beyond the placement of this item in the meeting notice.
The update remains within the factual scope required for regulatory disclosure and includes only the information recorded in the filing.
Particulars | Detailed Information |
Meeting Date | 6th December |
Agenda Item 1 | To review the investment by Biocon Biologics |
Agenda Item 2 | To finalise the fund raising plan |
Filing Type | Disclosure to the stock exchange |
Source of this Item | BSE |
The announcement is an example of Biocon's willingness to comply with disclosure rules & regulations set out by exchanges to provide its stakeholders with effective disclosure in a format for Stakeholder comparison. The update provides only confirmed information and is compiled in order of the items to be reviewed at the next Board Meeting.
As on 03-Dec-2025 at 15:30 PM IST, Biocon share price stood at ₹410.50, reflecting a movement of ₹11.50 (2.88%). The session recorded a previous close of ₹399.00, an open of ₹402.00, a high of ₹412.50, and a low of ₹400.05. The VWAP stood at ₹408.13, and the close price was ₹410.00.
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading